AbCellera Biologics (ABCL) Cash from Operations Growth (1y) (2021 - 2026)
AbCellera Biologics (ABCL) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
AbCellera Biologics |
1.55 Bn |
1.44 Bn |
- |
-190.14% |
| Date | Value |
|---|
| Mar 31, 2026 |
-190.14% |
| Dec 31, 2025 |
-334.29% |
| Sep 30, 2025 |
-82.10% |
| Jun 30, 2025 |
-8.14% |
| Mar 31, 2025 |
72.30% |
| Dec 31, 2024 |
59.21% |
| Sep 30, 2024 |
-27,147.17% |
| Jun 30, 2024 |
-250.56% |
| Mar 31, 2024 |
5.34% |
| Dec 31, 2023 |
-163.44% |
| Sep 30, 2023 |
99.92% |
| Jun 30, 2023 |
-92.71% |
| Mar 31, 2023 |
-143.97% |
| Dec 31, 2022 |
284.97% |
| Sep 30, 2022 |
-2,037.32% |
| Jun 30, 2022 |
73.14% |
| Mar 31, 2022 |
-8.51% |
| Dec 31, 2021 |
-1,407.67% |
| Sep 30, 2021 |
-56.06% |
| Jun 30, 2021 |
507.01% |
